Fosribnicotinamide

Fosribnicotinamide purchased from MedChemExpress. Usage Cited in: Theranostics. 2024 Apr 28;14(7):2794-2815. [Abstract]

Customer Validation
RAW264.7 cells were treated with FK866 (1 nM) and β-NMN (100 μΜ) 30 min before the addition of TGF-β1 (20 ng/mL) for 24 h，ELISA assay of NAMPT releasing in the culture supernatant (left), Quantification of the intracellular NAD level using a commercial kit (right).

Fosribnicotinamide purchased from MedChemExpress. Usage Cited in: Cell Metab. 2021 Jan 5;33(1):110-127.e5. [Abstract]

Customer Validation
Tumor growth curves and tumor burdens in C57BL/6 mice injected subcutaneously with sgCtrl or sgNampt liver cancer cells (Hepa1–6) for 3 weeks (n = 6) and C57BL/6 mice injected subcutaneously with Hepa1–6 cells with solvent control (Ctrl) or NMN (Fosribnicotinamide;300 mg/kg body weight; daily;intraperitoneal injection for 2 weeks beginning on day 7 after LLC cells, Pan02 cells, or Hepa1-6-CD38 cells were subcutaneously implanted).

Fosribnicotinamide purchased from MedChemExpress. Usage Cited in: Cell Metab. 2021 Jan 5;33(1):110-127.e5. [Abstract]

Customer Validation
Representative flow staining indicated cells in tumor xenograft of indicated groups.(NMN, Fosribnicotinamide;300 mg/kg body weight; daily;intraperitoneal injection for 2 weeks beginning on day 7 after LLC cells, Pan02 cells, or Hepa1-6-CD38 cells were subcutaneously implanted)

Fosribnicotinamide purchased from MedChemExpress. Usage Cited in: Cell Metab. 2021 Jan 5;33(1):110-127.e5. [Abstract]

Customer Validation
Representative flow staining (left panel) and frequency (right panel) of CD8+ T cells and PD-1+ CD8+ T cells in tumor xenograft of indicated groups ((NMN, Fosribnicotinamide;300 mg/kg body weight; daily,ip; PD-L1 antibodies (100 μg of anti-PD-L1 per mouse; twice a week) or combination via intraperitoneal injection for 2 weeks beginning on day 7 after LLC cells, Pan02 cells, or Hepa1-6-CD38 cells were subcutaneously implanted).

Fosribnicotinamide purchased from MedChemExpress. Usage Cited in: Proc Natl Acad Sci U S A. 2019 Sep 24;116(39):19626-19634. [Abstract]

Customer Validation
p53−/− mice were treated per divided lowdose Dox protocol and with either vehicle control or NMN (Fosribnicotinamide; 500 mg/kg, i.p., 3 times per week on alternating days) over the duration of the entire study. Unless indicated, all analyses were performed at study week 10. LV ejection fraction (LVEF) of p53−/−mice treated with Dox only or Dox plus NMN was measured by echocardiogram at study week 7 and 10 (n = 8). Mitochondrial respiration and ATP levels were measured in cardiac tissue (n ≥ 3).

Fosribnicotinamide purchased from MedChemExpress. Usage Cited in: Proc Natl Acad Sci U S A. 2019 Sep 24;116(39):19626-19634. [Abstract]

Customer Validation
p53−/− mice were treated per divided lowdose Dox protocol and with either vehicle control or NMN (Fosribnicotinamide; 500 mg/kg, i.p., 3 times per week on alternating days) over the duration of the entire study. Unless indicated, all analyses were performed at study week 10. Immunoblot of representative mtDNA-encoded protein MT-CO1 in cardiac tissue. GAPDH is shown as protein loading control.